While the genetic deletion of PARP2 is protective against nonalcoholic hepatic lipid accumulation (Bai et al. 2011a), there is apparent ambiguity in the literature on the role of PARP1 concerning whether the genetic ablation of PARP1 exacerbates NAFLD (Erener et al. 2012b) or pharmacological PARP inhibition protects against steatosis, inflammation, and liver tissue injury in NAFLD (Bai et al. 2011b; Gariani et al. 2017; Mukhopadhyay et al. 2017; Huang et al. 2018). The gene discussed is PARP2; the disease is metabolic dysfunction-associated steatotic liver disease.